SILO - Total Utang marang Modal silopharma.com

Logo perusahaan publik Silo Pharma (SILO)

This GURU.Markets chart illustrating the price evolution for Silo Pharma, Inc. (SILO) shows the separate_debt_total_eq metric at 0.00. Silo Pharma, Inc. has earned physician recognition through the synthesis of neurology and psychedelics while maintaining shareholder confidence. The business monetizes microdosing for the treatment of depression, leveraging patent protection. Meanwhile, R&D processes and production are fully outsourced to third-party contractors, creating a high dependency on vendors.

SILO: Total Utang marang Modal Silo Pharma 28.04.2023 - 31.10.2026

Rincian analitis perusahaan Silo Pharma, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Silo Pharma, Inc.|SILO - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Silo Pharma|SILO - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Silo Pharma|SILO - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku silopharma.com|SILO - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Silo Pharma, Inc.|SILO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Silo Pharma|SILO - Gunggung utang perusahaan|Utang marang nilai buku Silo Pharma|SILO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Silo Pharma|Likuiditas cepet silopharma.com
- informasi bathi lan kelipatan valuasi:
SILO - Asil keuangan resik
Analisis dhasar perusahaan:Silo Pharma, Inc.
Barang utama silopharma.com

Silo Pharma, Inc. (SILO) invests in the development of drugs for neurodegenerative pathologies without having a stable operating income. Analyzing the debt-to-equity chart, an investor can see the proportion of borrowed funds to equity assets, which is critical for assessing the company's financial stability given its dependence on clinical trial results and liquidity shortage risks.

Analisis pesaing Silo Pharma, Inc.

Utang marang Ekuitas Alkermes|Avadel Pharmaceuticals PLC - Utang Agregat marang Ekuitas|Total Utang marang Modal ATAI|GHRS (GH Research Group) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MNMD (Mind Medicine)|Total Utang marang Modal compasspathways.com CMPS|LBRX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi DRUG (Bright Minds Bio)|Vanda Pharmaceuticals Inc (VNDA) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Cybin|ANRO (Alto Neuroscience, Inc.) - Total Utang marang Modal|Total Utang marang Modal nrxpharma.com|Rasio Total Utang marang Ekuitas CING (Cingulate Inc.)|CPHI (chinapharmaholdings.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Clearmind Medicine CMND|PBM (Psyence Bio) - Utang Agregat marang Ekuitas|SPRC - Utang marang Ekuitas|Koefisien Total Utang marang Modal seelostherapeutics.com SEEL|VRPX (virpaxpharma.com) - Rasio Total Utang marang Ekuitas|Utang marang Modal Karuna Therapeutics Inc (KRTX)